Sagimet Biosciences Inc. (SGMT)
| Market Cap | 647.69M +205.5% |
| Revenue (ttm) | n/a |
| Net Income | -47.08M |
| EPS | -1.25 |
| Shares Out | 62.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,115,880 |
| Open | 11.23 |
| Previous Close | 11.09 |
| Day's Range | 10.15 - 11.26 |
| 52-Week Range | 4.50 - 11.45 |
| Beta | 3.48 |
| Analysts | Strong Buy |
| Price Target | 29.60 (+184.07%) |
| Est. Earnings | Nov 12, 2026 |
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for SGMT stock is "Strong Buy." The 12-month stock price target is $29.6, which is an increase of 184.07% from the latest price.
News
Sagimet Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Denifanstat, a novel FASN inhibitor, is advancing rapidly with strong phase III data in acne and MASH, a favorable safety profile, and FDA support for a single pivotal US trial including adolescents. Commercial plans target premium pricing, broad payer coverage, and a flexible launch strategy.
Cantor starts Sagimet at Overweight on potential in acne
Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Sagimet Biosciences (SGMT) with an Overweight rating and no price target The company is developing denifanstat for moderate-to-severe...
Sagimet Biosciences initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Sagimet Biosciences (SGMT) with an Overweight rating.
Sagimet Biosciences upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Sagimet Biosciences (SGMT) to Overweight from Equal Weight with a price target of $18, up from $8. The company’s dermatology prioritization is “smart” and will minimize spend while…
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabo...
Sagimet Biosciences advances AURORA clinical trial
Sagimet Biosciences (SGMT) announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4. Published first…
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWS...
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol...
Sagimet Biosciences price target raised to $56 from $49 at Canaccord
Canaccord raised the firm’s price target on Sagimet Biosciences (SGMT) to $56 from $49 and keeps a Buy rating on the shares. The firm said Sagimet reported financial results and…
Sagimet Biosciences price target raised to $29 from $12 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on Sagimet Biosciences (SGMT) to $29 from $12 and keeps an Outperform rating on the shares. The denifanstat outlook is improving…
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patie...
Sagimet Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
Denifanstat, a first-in-class oral FASN inhibitor, is advancing to phase III for moderate to severe acne after strong efficacy and safety results in China. The US trial will include adolescents and aims to address a large unmet need, with pricing expected above current oral antibiotics and topicals.
Sagimet Biosciences Quarterly report: Q2 2026
Sagimet Biosciences has published its Q2 2026 quarterly earnings report on August 11, 2026.
Sagimet Biosciences Earnings release: Q2 2026
Sagimet Biosciences released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol...
Sagimet Biosciences joins Russell 3000, Russell 2000 Indexes
Sagimet Biosciences (SGMT) announced that the company has been added to the broad-market Russell 3000 Index and small-cap Russell 2000 Index, effective at the open of U.S. equity markets today,…
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid reduc...
Sagimet Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Enhanced dermatology focus centers on denifanstat, a novel, well-tolerated oral acne therapy, with a U.S. phase III trial including adolescents set to start by year-end. Parallel development of a more potent molecule and topical formulations aims to expand reach, supported by strong safety data and recent financing.
Sagimet Biosciences price target lowered to $12 from $35 at Citizens
Citizens lowered the firm’s price target on Sagimet Biosciences (SGMT) to $12 from $35 and keeps an Outperform rating on the shares. Sagimet Biosciences is advancing denifanstat into a Phase…
Sagimet Biosciences price target lowered to $28 from $37 at Clear Street
Clear Street lowered the firm’s price target on Sagimet Biosciences (SGMT) to $28 from $37 and keeps a Buy rating on the shares. The firm is adjusting its model following…
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...
Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)
“Our recent strategic decision to focus on dermatology marks a turning point for Sagimet, and we are excited about the path ahead. In the near term, we are targeting the…
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 Fi...